Additional inhibitory checkpoints under investigation include TIM-3 and TIGIT, both of which are being evaluated in clinical trials for advanced solid tumors, though mesothelioma-specific data are not yet available [141]. The gene discussed is TIGIT; the disease is mesothelioma.